Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAL vs CUPRIMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Arsenic poisoning,Mercury poisoning,Lead poisoning (adjunct to edetate calcium disodium),Acute gold poisoning,Wilson's disease (investigational)
Wilson disease,Cystinuria,Rheumatoid arthritis (off-label)
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Primarily hepatic; undergoes oxidation and conjugation; metabolites excreted renally.
Metabolized by oxidation and reduction; primarily renal elimination.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
BAL is extensively bound to plasma proteins, primarily albumin, with protein binding >90%.
~70% bound, primarily to serum albumin.
Volume of distribution is approximately 3.5 L/kg, indicating extensive distribution into tissues, including brain and intracellular spaces.
Vd: 0.5–1.0 L/kg (approximately 70 L in adults). Indicates distribution into total body water with moderate tissue binding.
BAL is not administered orally due to poor absorption and gastrointestinal irritation. Given intravenously, bioavailability is 100%. Intramuscular bioavailability is similar but with slower absorption.
Oral: Approximately 40–70% (variable, reduced by food, especially high-protein meals; administration on empty stomach recommended).
GFR 10-50 m L/min: reduce frequency to every 6-8 hours; GFR <10 m L/min: reduce frequency to every 8-12 hours.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 25-50%. Monitor urinary copper and adjust accordingly.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% and monitor for hepatotoxicity.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to hepatotoxicity risk. Monitor liver function.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days; maximum 100 mg per dose.
10-20 mg/kg/day orally divided into 2-4 doses; typical starting dose 15 mg/kg/day for Wilson disease (max 1 g/day). Titrate based on urinary copper.
Start at 3 mg/kg IM every 6 hours; adjust based on renal function, monitor for hypotension and pain at injection site.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal decline; monitor renal function and copper levels.
None.
WARNING: CUPRIMINE can cause severe bone marrow depression leading to aplastic anemia, leukopenia, thrombocytopenia, and agranulocytosis. Deaths have occurred. Monitor blood counts closely.
Monitor renal function and serum electrolytes during therapy.,Can cause hypertension, tachycardia, and myocardial ischemia; use cautiously in cardiovascular disease.,May induce hemolytic anemia in patients with G6PD deficiency.,Injection site reactions and sterile abscesses may occur.,Iron deficiency is a known adverse effect due to iron chelation.
Bone marrow suppression, renal toxicity (proteinuria, hematuria), lupus-like syndrome, myasthenia gravis-like syndrome, rash, and hypersensitivity reactions. Monitor renal function, blood counts, and urinalysis regularly.
Hypersensitivity to BAL or any component.,Hepatic insufficiency (unless benefit outweighs risk).,Iron poisoning (forms toxic complex).,Concurrent use with cadmium or selenium (increased toxicity).
History of penicillamine-related aplastic anemia or agranulocytosis; concurrent gold therapy, antimalarial drugs, or immunosuppressants; rheumatoid arthritis patients with renal insufficiency.
Avoid alcohol and caffeine. Maintain adequate hydration. No specific food restrictions, but ensure iron-rich foods are avoided if concurrent iron poisoning suspected (though BAL not indicated for iron).
Take on an empty stomach. Avoid food, especially milk, and any mineral supplements (iron, zinc, calcium) for at least 1 hour before and 2 hours after dosing, as they reduce absorption. Alcohol should be avoided due to potential hepatotoxicity.
Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.
First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential for growth restriction. Third trimester: Risk of fetal copper deficiency and associated neurological impairment. Pregnancy category D.
BAL (dimercaprol) is excreted into breast milk; M/P ratio unknown. Limited data; exercise caution and consider temporary cessation of breastfeeding during therapy.
Excreted in breast milk. M/P ratio not established. Contraindicated in breastfeeding due to potential for severe adverse effects (hypersensitivity, bone marrow suppression) in the infant.
No specific dose adjustments recommended in pregnancy; monitor for increased volume of distribution and potential need for higher doses if toxicity persists.
No standard dose adjustment recommended; use lowest effective dose. Monitor serum copper to maintain therapeutic levels due to altered pharmacokinetics in pregnancy (increased volume of distribution, renal clearance).
BAL (dimercaprol) is used as a chelating agent for heavy metal poisoning, particularly arsenic, lead, and mercury. Administer deep IM only; avoid IV due to risk of hemolysis. Monitor blood pressure closely as hypertension can occur. Contraindicated in peanut allergy due to peanut oil vehicle. Administer with alkaline urine to protect kidneys.
Monitor for proteinuria and hematuria; perform urinalysis weekly initially, then monthly. Penicillamine can cause bone marrow suppression; obtain baseline CBC and differential, then monitor every 2 weeks for first 6 months, then monthly. Drug-induced lupus and myasthenia gravis are rare but serious autoimmune adverse effects. Avoid in patients with a history of penicillin allergy due to potential cross-sensitivity. Administer on an empty stomach at least 1 hour before or 2 hours after meals to enhance absorption. Dose adjustments needed in renal impairment. Pyridoxine (vitamin B6) supplementation (25-50 mg/day) is recommended to prevent deficiency caused by penicillamine. For Wilson disease, monitor 24-hour urinary copper excretion to guide therapy.
This medication is given as an injection into a muscle.,You may experience a metallic taste, headache, or nausea.,Report any signs of allergic reaction such as rash or difficulty breathing.,Avoid alcohol while on this medication.,Do not drive or operate heavy machinery until you know how this drug affects you.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not skip doses; take exactly as prescribed and do not double up if a dose is missed.,Report any signs of allergy promptly: rash, itching, fever, joint pain, or swollen lymph nodes.,Contact your doctor immediately if you experience easy bruising, bleeding, or signs of infection such as fever or sore throat.,Inform your doctor about any planned vaccinations; avoid live vaccines while on this medication.,You may need regular blood and urine tests to monitor for side effects.,If you are taking iron supplements or other mineral supplements, take them at least 2 hours apart from this medication to prevent reduced absorption.,Use effective contraception if you are of childbearing age; this drug can harm an unborn baby.,Avoid alcohol as it may increase the risk of liver toxicity.,Notify your dentist about your medication history before any dental procedures.
"Pregabalin, a gabapentinoid, enhances the inhibitory effects of GABA by binding to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Dapiprazole, an α1-adrenoceptor antagonist used for miosis, can have its therapeutic efficacy increased when combined with pregabalin due to additive central nervous system depression. This interaction may result in enhanced sedation, dizziness, and psychomotor impairment, potentially increasing the risk of falls and cognitive dysfunction."
"Pregabalin and pravastatin may exhibit an additive risk of musculoskeletal adverse effects, particularly myopathy and rhabdomyolysis, due to their overlapping effects on muscle cells. Pregabalin can cause dose-related muscle damage, while pravastatin inhibits HMG-CoA reductase, leading to reduced skeletal muscle integrity. This combination may potentiate serum creatine kinase elevations and increase the likelihood of clinical myopathy, especially in patients with predisposing factors such as renal impairment or concomitant use of other myotoxic agents."
"Pregabalin may cause fluid retention and peripheral edema, which can precipitate or exacerbate heart failure, especially in patients with pre-existing cardiac risk factors. Rosiglitazone, a thiazolidinedione, also promotes fluid retention and increases plasma volume via PPAR-γ-mediated renal effects. When combined, the additive fluid-retaining properties of both drugs can synergistically elevate the risk of new-onset or worsening heart failure, particularly in patients with reduced left ventricular function or NYHA Class III/IV status."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAL vs CUPRIMINE, answered by our medical review team.
BAL is a Chelating Agent that works by Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.. CUPRIMINE is a Chelating Agent that works by Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAL and CUPRIMINE depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAL is: 3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.. The standard adult dose of CUPRIMINE is: 250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAL and CUPRIMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAL is classified as Category C. Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.. CUPRIMINE is classified as Category C. First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.